Akebia Therapeutics is refocusing on Vafseo for dialysis patients, discontinuing expansion to non-dialysis, which has reset ...

Discover how add-on sales boost revenue with examples and benefits. Learn strategies for maximizing profits through effective ...

The most successful food and beverage brands today aren’t choosing between digital and physical retail, they’re mastering ...

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027$10 million milestone payment triggered from licensing agreement ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...

G&A Expense -- $1.9 million, down from $2.3 million mainly due to lower compensation and recruitment spending. Cash on ...

Pretax Loss -- $9.3 million, a significant reduction from the $29.9 million pretax loss in fiscal 2024, primarily due to ...

Ended the quarter with a 65% larger sales pipeline, shorter sales cycle, and higher average sales size. Customer Expansions - ...

A delayed environmental review cleared the Dakota Access Pipeline to continue operating. Separately, a North Dakota judge expressed unusual exasperation over the tangled legal battles. By Karen Zraick ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

Ottawa approves a framework allowing a privately financed oil pipeline to move Alberta crude to Asia, marking a major shift away from Canada’s decarbonization agenda. The project faces strong ...